Eye disease treatment developer Ocular Therapeutix has raised $65m from an initial public offering in which it floated below its range.

The life insurance company will target fintech, consumer internet, digital health and cybersecurity startups.

Sumitomo Dainippon and Taiho Pharmaceutical have each invested $30m in the firm, which will target early stage pharmaceutical companies.

Duke spin-out Regado Biosciences has had to halt its clinical trial.

Led by a group affiliated with Trimaran Capital Partners, the series B also included R2M Investments.

Augmenix has raised $10.8m in a series D round that will support the launch of its new hydrogel product.

Heart monitor developer Cardiac Insight has raised $7m in a series B round featuring Welch Allyn, a medical device maker with which it has signed a distribution deal.

Oxford University has entered into a research agreement with startup Big Health.